ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race

Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.

Read more »

Vertex Announces Positive Phase III Data for Hepatitis Drug

The New York Times reports that about 75 percent of patients taking telaprevir in combination with existing hepatitis C drugs were essentially cured of the virus, compared to 44 percent on standard therapy alone.

Read more »

Potential Hepatitis C Breakthrough for Santaris

In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.

Read more »